孤立性2型内漏对后续心血管事件及死亡率的影响
这项回顾性单中心研究纳入2010至2017年在里昂大学医院接受EVAR治疗且肾下腹主动脉瘤>50 mm的患者207例,按术后1年CTA是否存在孤立性EL2分为EL2+组60例与EL2-组147例,比较MACE、MALE及全因死亡率;EL2+组发生MACE或MALE的患者显著少于EL2-组(P=0.009),EL2-组随访期MALE风险更高,作者认为可能与基线下肢症状性外周动脉疾病更常见有关,建议密切随访并严格控制心血管危险因素。
要点
- 术后1年CTA无孤立性EL2的EVAR患者随访期MALE风险更高。
- EL2+组发生MACE或MALE的患者显著少于EL2-组(P=0.009)。
- EL2+组MALE发生率显著低于EL2-组(P=0.017)。
核心结论
- 接受EVAR治疗的AAA患者中,术后1年未出现EL2者随访期MALE风险更高,作者认为可能与基线症状性下肢外周动脉疾病更常见有关,并建议这类患者密切随访并严格控制心血管危险因素。
研究设计与样本
- 回顾性单中心研究,纳入2010至2017年里昂大学医院血管外科接受EVAR治疗且肾下AAA>50 mm的患者,共589例接受血管内手术、207例纳入分析。
- 按术后1年CTA是否存在孤立性EL2分为EL2+组60例(29%)与EL2-组147例(71%),比较MACE、MALE及全因死亡率。
主要发现
- 109例(53%)发生MACE或MALE,EL2+组发生MACE或MALE的患者显著少于EL2-组(P=0.009)。
- 47例(23%)发生至少1次MALE,EL2+组MALE发生率显著低于EL2-组(P=0.017)。
临床怎么用
- 作者认为术后1年未出现EL2的EVAR患者需要更密切的随访并严格控制心血管危险因素,以预防心血管疾病死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Assess subsequent cardiovascular events and all-cause mortality in patients with intact abdominal aortic aneurysm (AAA) treated by endovascular aneurysm repair (EVAR) according to the existence of isolated endoleak type 2 (EL2) at 1 year after EVAR implantation. METHODS: This retrospective, single-center study included patients treated with EVAR between 2010 and 2017 in the vascular surgery department of the University Hospital of Lyon with an infrarenal AAA > 50 mm. The baseline clinical characteristics collected just before EVAR were retrieved from electronic patient records of our institution. AAA characteristics, procedure, and the 1-year postoperative computed tomography angiography (CTA) were reported. Study end points, major adverse cardiovascular events (MACE), major adverse lower-extremity events (MALE), and all-cause mortality were recorded during follow-up. Patients were divided into 2 groups according to the presence of isolated EL2 (EL2 +) or absence (EL2 -) of any endoleak on CTA at 1 year. MACE, MALE, and all-cause mortality were compared between both groups. RESULTS: During the study period, 589 patients were treated by endovascular surgery and 207 were included. According to the CTA results at 1 year, 60 patients (29%) were included in the EL2 + group and 147 patients (71%) in the EL2 - group. A total of 109 patients (53%) experienced a MACE or MALE; significantly fewer patients in the EL2 + than in the EL2 - group did so (P = 0.009). There were 47 patients (23%) who experienced at least 1 MALE, and the frequency was significantly lower in the EL2 + group (P = 0.017). CONCLUSIONS: Patients with AAA treated by EVAR who did not develop EL2 at 1 year were at higher risk of MALE during follow-up. This might be explained by more frequent symptomatic lower extremity peripheral arterial disease at baseline in this group. These patients therefore require a closer follow-up and strict control of cardiovascular risk factors to prevent cardiovascular morbi-mortality.
引用
- Rivoire E, Tresson P, Pialoux V, et al. Impact of Isolated Type 2 Endoleak on Subsequent Cardiovascular Events and Mortality. Ann Vasc Surg. 2024. PMID: 38942363. doi:10.1016/j.avsg.2024.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。